Introduction: Neurology senior residents and stroke fellows are first to clinically assess and interpret imaging studies of patients presenting to the emergency department with acute stroke. The aim of this study was to compare the diagnostic accuracy of brain CT angiography (CTA) with and without CT perfusion (CTP) between neurology senior residents and stroke fellows. Methods: In this neuroimaging study, nine practitioners (four senior neurology residents (SNRs) and five stroke fellows (SFs)) clinically assessed and interpreted the imaging data of 50 cases (15 normal images, 21 large vessel occlusions (LVOs) and 14 medium vessel occlusions (MeVOs) in two sessions, 1 week apart in comparison to final diagnosis of experienced neuroradiologist and experienced stroke neurologist consensus. Interrater agreement of CTA alone and CTA with CTP was quantified using kappa statistics, sensitivity, specificity and overall accuracy. Results: Overall, arterial occlusions were correctly identified in 221/315 (70.1%) with CTA alone and in 266/315 (84.4%) with CTA and CTP (p < 0.001). The sensitivity of overall arterial occlusions detection with CTA alone was 94.2% (95% CI: 90.8%–96.6%) while with addition of CTP was 98% (95% CI: 95.6%–99.3%), The specificity of CTA alone was 74.7% (95% CI: 67.2%–81.3%) which increased with CTP to 84.4% (95% CI: 77.7%–89.8%). The likelihood of correct identification with CTA alone was 156/189 (82.54%) for LVOs and 65/126 (51.59%) for MeVOs. This increased to 169/189 (89.42%; p = 0.054) for LVOs and 97/126 (76.98%; p < 0.001) for MeVOs when the CTA images with CTP were viewed. There was good overall interrater agreement between readers when using CTA alone (k 0.71, 95% CI, 0.62–0.80) and almost perfect (k 0.85, 95% CI, 0.76–0.94) when CTP was added to the image for interpretation. CTA and CTP had a significantly lower median interquartile range (IQR) interpretation time than CTA alone (114 [IQR, 103–120] s vs 156 [IQR, 133–160] s, p < 0.001). Discussion: In cerebral arterial occlusions, the rate of LVO and MeVOs detections increases when adding CTP to CTA. The accuracy and time for diagnosing arterial occlusion can be significantly improved if CTP is added to CTA. As MeVOs are commonly missed by front-line neurology senior residents or stroke fellows, cases with significant deficits and no apparent arterial occlusions need to be reviewed with neuroradiological expertise.
Methotrexate (MTX) is potent chemotherapeutic agent, often administered intrathecally to treat or prevent central nervous system involvement in lymphomas and leukemias, particularly T-cell lymphoblastic leukemia (T-LBL). MTX has been linked to adverse neurologic effects that mimic acute stroke, including facial drooping, hemiplegia, impaired consciousness, and seizures, as well as changes on imaging—known as MTX-induced leukoencephalopathy (LE). We report a case of a 17-year-old male diagnosed with T-LBL, who had been receiving MTX chemotherapy for 4 months. After receiving his fourth dose of MTX, he presented to the emergency department with fever, facial drooping, and acute left-sided weakness. Brain magnetic resonance imaging (MRI) revealed bilateral deep white matter T2 hyperintense foci, increased on the right, with associated diffusion restriction in the right centrum semiovale—consistent with MTX-induced LE. After his symptoms resolved, he was discharged on leucovorin. Six months afterward, he was rechallenged with MTX and developed recurrence of symptoms. Repeat MRI showed well-defined T2/FLAIR hyperintensities in the right centrum semiovale without corresponding diffusion restriction. The left centrum semiovale hyperintensity became less conspicuous in comparison to the previous MRI study. We report a rare case of recurrence of LE after MTX rechallenge and discuss mechanisms, best imaging modalities, and possible treatment options for MTX-induced LE. Given the ominous presentation of MTX-induced LE, we urge clinicians to maintain a high index of suspicion for this condition. Further research is necessary to understand why only certain patients develop recurrence of LE after subsequent doses of MTX.
Background: Despite the excellent recanalization rates following thrombectomy, significantly fewer patients have favorable outcomes. Impaired reperfusion of the microcirculation caused by distal thrombi could contribute to that, and adjunctive intraarterial thrombolysis such as alteplase (IA-tPA) might improve outcomes. We assessed the impact of adjunctive IA-tPA following thrombectomy with TICI score 2A on functional outcomes and reperfusion status. Methods: A retrospective analysis of patients with LVO ischemic stroke who underwent EVT. Patients were dichotomized into those who received EVT + IA-tPA vs EVT alone. Primary outcomes were favorable functional outcome (90-day mRS 0–2), and 90-day home-time. Results: 354 patients were included, of which 133 (37.6%) were treated with EVT + IA-tPA and 221 (62.4%) were treated with EVT alone. Baseline characteristics were similar in both groups. The non-IA-tPA group had a significant proportion of patients with higher baseline TICI scores (P < 0.0001). There was no significant difference in the rate of favorable functional outcomes between patients who received IA-tPA vs those who did not (59.8% vs 66.1%; p = 0.27), 90-day home time was 77 (69–83) vs 66 (60–81) days, p = 0.26. There was no difference in the rate of sICH (2.2% vs 2.3%; P = 0.99), and mortality (15% vs 8.3%; P = 0.06). IA-tPA resulted in a significant improvement in TICI scores from 33.3% to 62.9% and was 3.4 times more likely to improve reperfusion status. Conclusion: IA-tPA following thrombectomy with TICI score 2A appeared to be safe and improved the final TICI score; however, this angiographic improvement did not translate into functional outcomes.
Background: Intracranial atherosclerotic disease (ICAD) is a leading cause of ischemic stroke worldwide, with a significant prevalence in specific populations. This study aims to compare the clinical characteristics, imaging profiles, and outcomes of stroke patients with large vessel occlusion (LVO) caused by ICAD versus non-ICAD etiologies, particularly in those transferred for endovascular treatment (EVT). Methods: A retrospective analysis was conducted using data from the Riyadh Thrombectomy Registry, including 219 patients with acute ischemic stroke who underwent EVT between January 2019 and March 2024. Clinical, demographic, and imaging data were collected and compared between ICAD and non-ICAD groups. Imaging modalities included computed tomography perfusion (CTP) and angiography, with key metrics such as the hypoperfusion intensity ratio (HIR) and cerebral blood volume (CBV) index evaluated for prognostic utility. Results: Patients with ICAD were older and demonstrated a higher prevalence of vascular risk factors. ICAD patients presented with better ASPECTS scores, smaller ischemic core volumes, and higher mismatch ratios, reflecting better collateral circulation. However, despite favorable imaging profiles, ICAD patients exhibited higher mortality rates, particularly in cases involving basilar artery occlusion. HIR and CBV indices demonstrated modest diagnostic performance in distinguishing ICAD from non-ICAD, with an area under the curve (AUC) of 0.62 for HIR and 0.57 for CBV. Conclusions: ICAD patients undergoing EVT showed distinct clinical and imaging characteristics compared to non-ICAD patients. Despite better collateral circulation, ICAD is associated with higher mortality, especially in posterior circulation strokes. Further research is required to optimize EVT strategies and explore adjunctive therapies tailored to this challenging patient population.
Background: Following transient ischemic attack (TIA) and minor stroke, the risk of recurrent stroke can be significantly reduced with short-duration dual antiplatelet therapy (DAPT). We wish to investigate whether 10 days of DAPT is as effective as 21 days’ treatment. Study design: This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA + clopidogrel) is non-inferior to 21 days of DAPT in patients with acute ischemic stroke (AIS) or high-risk TIA. In both groups, DAPT is started within 24 hours of symptom onset. This study is being conducted in approximately 15 study sites in the Kingdom of Saudi Arabia. The planned sample size is 1932. Outcomes: Non-inferiority of 10 days compared to 21 days of DAPT in the prevention of the composite endpoint of stroke and death at 90 days in AIS/TIA patients. The primary safety outcome is major intra-cranial and systemic hemorrhage. Study period: Enrolment started in the second quarter of 2023, and the completion of the study is expected in the fourth quarter of 2025. Discussion: The trial is expected to show that 10 days of DAPT is non-inferior for the prevention of early recurrence of vascular events in patients with high-risk TIAs and minor strokes.